# Duquesne Family Office

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/duquesne-family-office
Canonical HTML page: https://getbiobrief.com/entity/duquesne-family-office

## Timeline

- **2026**: Duquesne Family Office initiates RYTM position — In Q2 2026, Stanley Druckenmiller's investment firm discloses a new stake in Rhythm Pharmaceuticals.
- **2022**: FDA expands Imcivree approval to Bardet-Biedl syndrome — The indication is expanded to cover obesity associated with Bardet-Biedl syndrome.
- **2020**: FDA approves Imcivree for POMC deficiency — Imcivree receives U.S. approval for chronic weight management in patients with proopiomelanocortin deficiency.

## Recent coverage (1 stories)

### Druckenmiller's Q2 RYTM Bet Targets 2 FDA Nods in Rare Obesity
2026-08-24 02:26:37 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Biotech investors are tracking Rhythm Pharmaceuticals after Duquesne Family Office disclosed a Q2 2026 stake. Imcivree's 2020 and 2022 FDA approvals for POMC deficiency and Bardet-Biedl syndrome give RYTM an orphan monopoly in a niche GLP-1 leaders can't enter.
Full story: https://getbiobrief.com/story/druckenmiller-rhythm-fda-rare-obesity-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.